Just Biotherapeutics and Teva Enter an Agreement for the Design and Development of a High Productivity (HP) Biomanufacturing Process

With the goal of significantly lowering the cost of manufacturing, Just will use its extensive knowledge and technological expertise on the design and development of a high yielding manufacturing process for one of Teva’s more complex products in development. Both companies firmly believe that innovation in both biologics development and manufacturing can play a role in increasing patient access.

“Just’s deep expertise in engineering and manufacturing of biotherapeutics combined with their unique technology platform will enable Teva to work toward developing processes that will help achieve greater efficiencies and improved outputs. We value our partnership with Just in that it will help accelerate our ability to advance our Teva mission of improving the lives of patients,” said Steffen Nock, Senior Vice President of Teva Specialty R&D.

“We are delighted to leverage our deep experience to assist Teva in their biologics efforts,” said Dr. James Thomas, co-founder and Chief Executive Officer of Just. “Working with a multinational company, like Teva, will create greater access to biologics through the technological innovation that Just will deliver.”

The collaboration will be enabled by a cross-functional team based at Just’s facility in Seattle, WA working together with Teva’s Specialty R&D team based in West Chester, PA.

About Just Biotherapeutics

Just is a unique platform company that integrates the design, engineering, development, and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the Just team came together to solve the scientific and technical hurdles that block access to life-changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus is to create access and value for a global market through scientific and technological innovation. Just has recently signed a definitive agreement with Evotec SE to become a fully owned subsidiary, and part of the Evotec family. Learn more at www.just.bio.

About Teva

Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 35,000 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190628005023/en/